Axsome Therapeutics Inc is presenting four posters on Sunosi (solriamfetol), approved for patients with excessive daytime sleepiness due to narcolepsy and obstructive sleep apnea (OSA), at the 2023 Psych Congress, being held in Nashville from Sept 6-10.
One poster will feature results from the SHARP study, a trial of Sunosi in 59 patients with excessive daytime sleepiness associated with OSA and impaired cognitive function. Positive topline results were announced in October 2022.
“These presentations explore the meaningful impact that our treatments could have for patients and underscore the unique pharmacology of our novel medicines which may be relevant to multiple clinical conditions,” says Cecilia Brain, MD, PhD, vice president of medical affairs at Axsome, in a release.
Key highlights include data examining the effects of Sunosi on cognition in patients with excessive daytime sleepiness and OSA and data examining treatment effect sizes of Sunosi in patients with excessive daytime sleepiness associated with narcolepsy and OSA.
Details for the presentations are as follows:
Title: Effects of Solriamfetol on Cognitive Function in Participants With Cognitive Impairment Associated With Excessive Daytime Sleepiness in Obstructive Sleep Apnea: Results of the SHARP Study
Lead author: Hans Van Dongen, PhD, Washington State University
Poster number: 32
Title: Solriamfetol Improves Cognitive Performance in Preclinical Models of Sleep Apnea and in a Randomized Placebo-Controlled Study of Sleep Apnea Participants (SHARP)
Lead author: David Gozal, MD, University of Missouri
Poster number: 33
Title: Solriamfetol for Excessive Sleepiness in Narcolepsy and Obstructive Sleep Apnea: Effect Sizes and Numbers Needed to Treat or Harm
Lead author: Craig Chepke, MD, SUNY Upstate Medical University
Poster number: 45
Title: SURWEY Study of Solriamfetol: Initiation, Titration, Safety, Efficacy, and Follow-Up Experience for Patients With OSA in Germany
Lead author: Yaroslav Winter, MD, Mainz Comprehensive Epilepsy and Sleep Medicine Center, department of neurology, Johannes Gutenberg-University, Mainz, Germany
Poster number: 99
